A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Stopped early · Phase 1

Conditions studied: Breast Cancer Metastatic, Locally Advanced Breast Cancer (LABC), Malignant Neoplasm of Breast, Triple Negative Breast Cancer (TNBC), Hormone Receptor-Positive Breast Cancer, HER2 + Breast Cancer

In brief

The goal of this clinical trial is to evaluate CLBR001 and ABBV-461 as a treatment for patients with locally advanced or metastatic breast cancer. The goals are to establish the safety and efficacy of the combination therapy while establishing the optimal biologic doses. Patients will be administered a single infusion of CLBR001 cells followed by cycles of ABBV-461 with regular assessments of safety and disease response to treatment.

Key facts

Study ID

NCT06878248

Run by

Calibr, a division of Scripps Research

People needed

10

Starts

2025-04-17

Expected to finish

2026-04-09

Last updated by the study team

2026-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Refractory or relapsed locally advanced or metastatic breast cancer
• Exhaused all standard of care therapy options
• Measurable disease at time of screening in accordance with RECIST v1.1 criteria
• Women or men age ≥18 years of age at time of consent
• ECOG performance status 0 or 1
• Must provide a biopsy sample obtained during the screening period, following the end of the most recent prior line of therapy
• Adequate hematological, renal, and liver function

You may not qualify if…

• History of a clinically significant infection within 4 weeks prior to consent
• Active bacterial, viral, and/or fungal infection
• Prior allogeneic stem cell transplant
• Prior lentiviral- or retroviral-based therapy including CAR-T cell therapy
• Prior lymphodepleting or T-cell cytotoxic therapy within 3 months of enrollment
• Subjects receiving attenuated vaccines within 4 weeks of consent or need for live vaccine within 12 months of starting study therapy
• History of significant cardiovascular conditions within the past 6 months
• Subjects with a prior history of or concurrent malignancy whose natural history or treatment has the potential to interfere with either the safety or efficacy assessment of the investigational regimen

Where it is running

• Augusta University Medical Center — Augusta, Georgia, United States
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• University of Virginia — Charlottesville, Virginia, United States
• Fred Hutchinson Cancer Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.